Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
New England Journal of Medicine2018Vol. 379(11), pp. 1007–1016
Citations Over TimeTop 1% of 2018 papers
Matthew J. Maurer, Jeffrey H. Schwartz, Balarama Gundapaneni, Perry Elliott, Giampaolo Merlini, Márcia Waddington‐Cruz, Arnt V. Kristen, Martha Grogan, Ronald Witteles, Thibaud Damy, Brian Drachman, Sanjiv J. Shah, Mazen Hanna, Daniel P. Judge, Alexandra I. Barsdorf, Peter M. Huber, Terrell A. Patterson, Steve Riley, Jennifer Schumacher, Michelle Stewart, Marla B. Sultan, Claudio Rapezzi
Abstract
In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo. (Funded by Pfizer; ATTR-ACT ClinicalTrials.gov number, NCT01994889 .).
Related Papers
- → Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis(2021)9 cited
- Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type.(1983)
- → Transthyretin is synthesized in the mammalian eye(1988)57 cited
- → Variant transthyretin in cerebrospinal fluid in familial amyloidotic polyneuropathy(1987)20 cited
- → Transthyretin: Its Functions and Involvement in the Pathogenicity of Various Diseases(2009)